The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Nov. 06, 2014
Applicants:

Universite DE Rennes 1, Rennes, FR;

Centre National DE LA Recherche Scientifique—cnrs-, Paris, FR;

Centre Hospitalier Universitaire Pontchaillou, Rennes, FR;

Inventors:

David Gilot, Goven, FR;

Marie-Dominique Galibert, Rennes, FR;

Ghanem Ghanem, Drogenbos, BE;

Fabrice Journe, Blaregnies, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12Q 1/6886 (2018.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12N 15/1137 (2013.01); C12N 15/1138 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01); C12Q 2600/178 (2013.01); C12Y 114/18 (2013.01);
Abstract

The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients' survival irrespective of the treatment administered.


Find Patent Forward Citations

Loading…